{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:13:35Z","timestamp":1778584415574,"version":"3.51.4"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03530-6","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:59:15Z","timestamp":1773820755000},"page":"1926-1947","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Burden, Outcomes, and Management of Patients with Aldosterone Dysregulation: A Targeted Literature Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Gianfranco","family":"Parati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gbenga","family":"Ogedegbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abiy","family":"Agiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrison","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"McKendrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3215-9118","authenticated-orcid":false,"given":"Raymond R.","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"3530_CR1","volume-title":"Physiology, aldosterone","author":"JH Scott","year":"2024","unstructured":"Scott JH, Menouar MA, Dunn RJ. Physiology, aldosterone. Treasure Island: StatPearls; 2024."},{"key":"3530_CR2","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1210\/jc.2003-030490","volume":"88","author":"JS Williams","year":"2003","unstructured":"Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biom13061004","author":"M Crompton","year":"2023","unstructured":"Crompton M, Skinner LJ, Satchell SC, Butler MJ. Aldosterone: essential for life but damaging to the vascular endothelium. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13061004.","journal-title":"Biomolecules"},{"key":"3530_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157436212800376708","volume":"7","author":"A Verhovez","year":"2012","unstructured":"Verhovez A, Williams TA, Monticone S, et al. Genomic and non-genomic effects of aldosterone. Curr Signal Transduct Ther. 2012;7:132\u201341.","journal-title":"Curr Signal Transduct Ther"},{"key":"3530_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173:10\u201320.","journal-title":"Ann Intern Med"},{"key":"3530_CR6","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.1210\/clinem\/dgad512","volume":"109","author":"YE Yuan","year":"2024","unstructured":"Yuan YE, Haas AV, Rosner B, Adler GK, Williams GH. Elevated blood pressure and aldosterone dysregulation in young black women versus white women on controlled sodium diets. J Clin Endocrinol Metab. 2024;109:e773\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR7","volume-title":"Endotext","author":"N Papadopoulou-Marketou","year":"2000","unstructured":"Papadopoulou-Marketou N, Vaidya A, Dluhy R, Chrousos GP, et al. Hyperaldosteronism. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Endotext. South Dartmouth: MDText.com Inc; 2000."},{"key":"3530_CR8","volume-title":"Physiology, aldosterone","author":"JH Scott","year":"2025","unstructured":"Scott JH, Menouar MA, Dunn RJ. Physiology, aldosterone. Treasure Island (FL): StatPearls; 2025."},{"key":"3530_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33\u201341.","journal-title":"N Engl J Med"},{"key":"3530_CR10","unstructured":"Million Hearts\u00ae. Estimated hypertension prevalence, treatment, and control among US adults. https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence.htmlAccessed. Accessed Jun 2024."},{"key":"3530_CR11","unstructured":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398:957\u201380."},{"key":"3530_CR12","unstructured":"World Health Federation. World hypertension day: taking action against the silent epidemic of high blood pressure. World Heart Federation website. 2022. https:\/\/world-heart-federation.org\/news\/world-hypertension-day-taking-action-against-the-silent-epidemic-of-high-blood-pressure\/ Accessed 21 May 2025."},{"key":"3530_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0000000000002216","volume":"38","author":"S Monticone","year":"2020","unstructured":"Monticone S, Sconfienza E, D\u2019Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis. J Hypertens. 2020;38:3\u201312.","journal-title":"J Hypertens"},{"key":"3530_CR14","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1093\/eurheartj\/ehac352","volume":"43","author":"A Verma","year":"2022","unstructured":"Verma A, Vaidya A, Subudhi S, Waikar SS. Aldosterone in chronic kidney disease and renal outcomes. Eur Heart J. 2022;43:3781\u201391.","journal-title":"Eur Heart J"},{"key":"3530_CR15","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","volume":"31","author":"A Tomaschitz","year":"2010","unstructured":"Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237\u201347.","journal-title":"Eur Heart J"},{"key":"3530_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3530_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tem.2012.09.004","volume":"24","author":"BJ He","year":"2013","unstructured":"He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab. 2013;24:21\u201330.","journal-title":"Trends Endocrinol Metab"},{"key":"3530_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJMe2216143","volume":"388","author":"M Azizi","year":"2023","unstructured":"Azizi M. Decreasing the effects of aldosterone in resistant hypertension\u2014a success story. N Engl J Med. 2023;388:461\u20133.","journal-title":"N Engl J Med"},{"key":"3530_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41440-023-01188-z","volume":"46","author":"H Ando","year":"2023","unstructured":"Ando H. Inhibition of aldosterone synthase: does this offer advantages compared with the blockade of mineralocorticoid receptors? Hypertens Res. 2023;46:1056\u20137.","journal-title":"Hypertens Res"},{"key":"3530_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007;3:486\u201392.","journal-title":"Nat Clin Pract Nephrol"},{"key":"3530_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684111","volume":"12","author":"P J\u0119drusik","year":"2021","unstructured":"J\u0119drusik P, Symonides B, Lewandowski J, Gaciong Z. The effect of antihypertensive medications on testing for primary aldosteronism. Front Pharmacol. 2021;12:684111.","journal-title":"Front Pharmacol"},{"key":"3530_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","volume":"149","author":"B Pitt","year":"2024","unstructured":"Pitt B, Williams GH. Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators? Circulation. 2024;149:414\u20136.","journal-title":"Circulation"},{"key":"3530_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/HYPERTENSIONAHA.120.15950","volume":"77","author":"M Siddiqui","year":"2021","unstructured":"Siddiqui M, Judd EK, Zhang B, et al. Masked uncontrolled hypertension is accompanied by increased out-of-clinic aldosterone secretion. Hypertension. 2021;77:435\u201344.","journal-title":"Hypertension"},{"key":"3530_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s10462-024-10902-3","volume":"57","author":"F Bola\u00f1os","year":"2024","unstructured":"Bola\u00f1os F, Salatino A, Osborne F, Motta E. Artificial intelligence for literature reviews: opportunities and challenges. Artif Intell Rev. 2024;57:259.","journal-title":"Artif Intell Rev"},{"key":"3530_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/HJH.0000000000000076","volume":"32","author":"C Lonati","year":"2014","unstructured":"Lonati C, Bassani N, Gritti A, Biganzoli E, Morganti A. Measurement of plasma renin concentration instead of plasma renin activity decreases the positive aldosterone-to-renin ratio tests in treated patients with essential hypertension. J Hypertens. 2014;32:627\u201334.","journal-title":"J Hypertens"},{"key":"3530_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","volume":"76","author":"K Inoue","year":"2020","unstructured":"Inoue K, Goldwater D, Allison M, Seeman T, Kestenbaum BR, Watson KE. Serum aldosterone concentration, blood pressure, and coronary artery calcium: the multi-ethnic study of atherosclerosis. Hypertension. 2020;76:113\u201320.","journal-title":"Hypertension"},{"key":"3530_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7326\/M17-0882","volume":"167","author":"JM Brown","year":"2017","unstructured":"Brown JM, Robinson-Cohen C, Luque-Fernandez MA, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: a cohort study. Ann Intern Med. 2017;167:630\u201341.","journal-title":"Ann Intern Med"},{"key":"3530_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2021.10.149","volume":"345","author":"J Biegus","year":"2021","unstructured":"Biegus J, Nawrocka-Millward S, Zymli\u0144ski R, et al. Distinct renin\/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. Int J Cardiol. 2021;345:54\u201360.","journal-title":"Int J Cardiol"},{"key":"3530_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1017177","volume":"13","author":"L Gan","year":"2022","unstructured":"Gan L, Li N, Heizhati M, et al. Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data. Front Endocrinol (Lausanne). 2022;13:1017177.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3530_CR30","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2147\/DMSO.S408722","volume":"16","author":"J Hu","year":"2023","unstructured":"Hu J, Cai X, Zhu Q, et al. Relationship between plasma aldosterone concentrations and non-alcoholic fatty liver disease diagnosis in patients with hypertension: a retrospective cohort study. Diabetes Metab Syndr Obes. 2023;16:1625\u201336.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3530_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023082","volume":"10","author":"J Hu","year":"2021","unstructured":"Hu J, Shen H, Huo P, et al. Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: a collaborative study. J Am Heart Assoc. 2021;10:e023082.","journal-title":"J Am Heart Assoc"},{"key":"3530_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11427-021-1945-6","volume":"65","author":"B Ke","year":"2022","unstructured":"Ke B, Tan X, Ren L, et al. Aldosterone dysregulation predicts the risk of mortality and rehospitalization in heart failure with a preserved ejection fraction. Sci China Life Sci. 2022;65:631\u201342.","journal-title":"Sci China Life Sci"},{"key":"3530_CR33","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/HYPERTENSIONAHA.121.18342","volume":"79","author":"Q Zhu","year":"2022","unstructured":"Zhu Q, Heizhati M, Lin M, et al. Higher plasma aldosterone concentrations are associated with elevated risk of aortic dissection and aneurysm: a case-control study. Hypertension. 2022;79:736\u201346.","journal-title":"Hypertension"},{"key":"3530_CR34","doi-asserted-by":"publisher","first-page":"2301571","DOI":"10.1080\/10641963.2023.2301571","volume":"46","author":"C He","year":"2024","unstructured":"He C, Li R, Yang J, et al. Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study. Clin Exp Hypertens. 2024;46:2301571.","journal-title":"Clin Exp Hypertens"},{"key":"3530_CR35","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/HJH.0000000000003377","volume":"41","author":"RM Alnazer","year":"2023","unstructured":"Alnazer RM, Veldhuizen GP, de Leeuw PW, Kroon AA. The effect of age, sex and BMI on the aldosterone-to-renin ratio in essential hypertensive individuals. J Hypertens. 2023;41:618\u201323.","journal-title":"J Hypertens"},{"key":"3530_CR36","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ehf2.12634","volume":"7","author":"M Kobayashi","year":"2020","unstructured":"Kobayashi M, Stienen S, Ter Maaten JM, et al. Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Fail. 2020;7:953\u201363.","journal-title":"ESC Heart Fail"},{"key":"3530_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cen.14199","volume":"93","author":"P Solanki","year":"2020","unstructured":"Solanki P, Gwini SM, Doery JCG, et al. Age- and sex-specific reference ranges are needed for the aldosterone\/renin ratio. Clin Endocrinol (Oxf). 2020;93:221\u20138.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"3530_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/08037051.2019.1645587","volume":"29","author":"LF Gafane-Matemane","year":"2020","unstructured":"Gafane-Matemane LF, Mokae NL, Breet Y, Malan L. Relation of the renin-angiotensin-aldosterone system with potential cardiac injury and remodelling: the SABPA study. Blood Press. 2020;29:31\u20138.","journal-title":"Blood Press"},{"key":"3530_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7812\/TPP\/23.096","volume":"28","author":"V Kim","year":"2024","unstructured":"Kim V, Shi J, An J, et al. Hyperaldosteronism screening and findings from a large diverse population with resistant hypertension within an integrated health system. Perm J. 2024;28:3\u201313.","journal-title":"Perm J"},{"key":"3530_CR40","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ajh\/hpt276","volume":"27","author":"DE Rifkin","year":"2014","unstructured":"Rifkin DE, Khaki AR, Jenny NS, et al. Association of renin and aldosterone with ethnicity and blood pressure: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2014;27:801\u201310.","journal-title":"Am J Hypertens"},{"key":"3530_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/1573402114666171213145049","volume":"14","author":"AA Akintunde","year":"2018","unstructured":"Akintunde AA, Salawu AA, Oloyede T, Adeniyi DB. Renin activity and aldosterone assay among Nigerians with hypertension and normotension: an insight into normative values and clinical correlates. Curr Hypertens Rev. 2018;14:29\u201334.","journal-title":"Curr Hypertens Rev"},{"key":"3530_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.114.03311","volume":"64","author":"R Deo","year":"2014","unstructured":"Deo R, Yang W, Khan AM, et al. Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension. 2014;64:103\u201310.","journal-title":"Hypertension"},{"key":"3530_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/HYPERTENSIONAHA.121.17336","volume":"78","author":"J Yang","year":"2021","unstructured":"Yang J, May Gwini S, Beilin LJ, et al. Relationship between the aldosterone-to-renin ratio and blood pressure in young adults: a longitudinal study. Hypertension. 2021;78:387\u201396.","journal-title":"Hypertension"},{"key":"3530_CR44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.116.07806","volume":"68","author":"T Dudenbostel","year":"2016","unstructured":"Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA. Body mass index predicts 24-hour urinary aldosterone levels in patients with resistant hypertension. Hypertension. 2016;68:995\u20131003.","journal-title":"Hypertension"},{"key":"3530_CR45","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ajh\/hpaa208","volume":"34","author":"T Dudenbostel","year":"2021","unstructured":"Dudenbostel T, Li P, Calhoun DA. Paradoxical increase of 24-hour urinary aldosterone levels in obese patients with resistant hypertension on a high salt diet. Am J Hypertens. 2021;34:600\u20138.","journal-title":"Am J Hypertens"},{"key":"3530_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.31351\/vol28iss1pp53-63","volume":"28","author":"BH Salih","year":"2019","unstructured":"Salih BH, H.Ali S, I. Allehibi K. Serum aldosterone levels in patients with diabetic nephropathy in relation to vascular calcification. Iraqi J Pharm Sci. 2019;28:53\u201363.","journal-title":"Iraqi J Pharm Sci"},{"key":"3530_CR47","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/jch.13041","volume":"19","author":"A Tirosh","year":"2017","unstructured":"Tirosh A, Hannah-Shmouni F, Lyssikatos C, et al. Obesity and the diagnostic accuracy for primary aldosteronism. J Clin Hypertens (Greenwich). 2017;19:790\u20137.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3530_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/HYPERTENSIONAHA.114.03936","volume":"65","author":"A Buglioni","year":"2015","unstructured":"Buglioni A, Cannone V, Cataliotti A, et al. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension. 2015;65:45\u201353.","journal-title":"Hypertension"},{"key":"3530_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/jhh.2014.40","volume":"29","author":"MA Allison","year":"2015","unstructured":"Allison MA, Jenny NS, McClelland RL, Cushman M, Rifkin D. The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. J Hum Hypertens. 2015;29:127\u201333.","journal-title":"J Hum Hypertens"},{"key":"3530_CR50","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.endmts.2023.100126","volume":"11","author":"G Lee","year":"2023","unstructured":"Lee G, Kluwe B, Zhao S, et al. Adiposity, aldosterone and plasma renin activity among African Americans: The Jackson Heart Study. Endocr Metab Sci. 2023;11:100126.","journal-title":"Endocr Metab Sci."},{"key":"3530_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028718","volume":"12","author":"YE Yuan","year":"2023","unstructured":"Yuan YE, Haas AV, Williams GH, Taylor H, Seely EW, Adler GK. Association between life\u2019s simple 7 and biomarkers of cardiovascular disease: aldosterone, interleukin-6, c-reactive protein. J Am Heart Assoc. 2023;12:e028718.","journal-title":"J Am Heart Assoc"},{"key":"3530_CR52","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6017105","volume":"2020","author":"N Alaagib","year":"2020","unstructured":"Alaagib N, Sukkar M, Kardash M. The effects of salt and glucose intake on angiotensin II and aldosterone in obese and nonobese patients with essential hypertension. Int J Hypertens. 2020;2020:6017105.","journal-title":"Int J Hypertens"},{"key":"3530_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-46285-8","volume":"13","author":"N Graudal","year":"2023","unstructured":"Graudal N, Hubeck-Graudal T, Jurgens G. A low dietary sodium dose is associated with a more pronounced aldosterone response in normotensive than in hypertensive individuals. Sci Rep. 2023;13:19027.","journal-title":"Sci Rep"},{"key":"3530_CR54","volume":"12","author":"NA Graudal","year":"2020","unstructured":"Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev. 2020;12:CD004022.","journal-title":"Cochrane Database Syst Rev"},{"key":"3530_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/08037051.2023.2291411","volume":"33","author":"K Mansouri","year":"2024","unstructured":"Mansouri K, Greupner T, Hahn A. Blood pressure stability and plasma aldosterone reduction: the effects of a sodium and bicarbonate-rich water\u2014a randomized controlled intervention study. Blood Press. 2024;33:2291411.","journal-title":"Blood Press"},{"key":"3530_CR56","doi-asserted-by":"publisher","DOI":"10.1093\/cdn\/nzz091","volume":"3","author":"SA Maris","year":"2019","unstructured":"Maris SA, Williams JS, Sun B, Brown S, Mitchell GF, Conlin PR. Interactions of the DASH diet with the renin-angiotensin-aldosterone system. Curr Dev Nutr. 2019;3:nzz091.","journal-title":"Curr Dev Nutr"},{"key":"3530_CR57","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1470320314526437","volume":"15","author":"SJ Shin","year":"2014","unstructured":"Shin SJ, Lim C, Oh SW, Rhee MY. The unique response of renin and aldosterone to dietary sodium intervention in sodium sensitivity. J Renin Angiotensin Aldosterone Syst. 2014;15:117\u201323.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"3530_CR58","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","volume":"79","author":"JM Brown","year":"2022","unstructured":"Brown JM, Wijkman MO, Claggett BL, et al. Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study. Hypertension. 2022;79:1984\u201393.","journal-title":"Hypertension"},{"key":"3530_CR59","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12882-017-0789-x","volume":"18","author":"CM Gant","year":"2017","unstructured":"Gant CM, Laverman GD, Vogt L, et al. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol. 2017;18:370.","journal-title":"BMC Nephrol"},{"key":"3530_CR60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/ajh\/hpu161","volume":"28","author":"I Hajjar","year":"2015","unstructured":"Hajjar I, Hart M, Mack W, Lipsitz LA. Aldosterone, cognitive function, and cerebral hemodynamics in hypertension and antihypertensive therapy. Am J Hypertens. 2015;28:319\u201325.","journal-title":"Am J Hypertens"},{"key":"3530_CR61","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1210\/jc.2016-1002","volume":"101","author":"JJ Joseph","year":"2016","unstructured":"Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR, et al. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson Heart Study. J Clin Endocrinol Metab. 2016;101:1770\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR62","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1161\/CIRCULATIONAHA.120.050896","volume":"143","author":"JJ Joseph","year":"2021","unstructured":"Joseph JJ, Pohlman NK, Zhao S, et al. Association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson Heart Study. Circulation. 2021;143:2355\u201366.","journal-title":"Circulation"},{"key":"3530_CR63","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cardfail.2021.08.015","volume":"28","author":"Y Lytvyn","year":"2022","unstructured":"Lytvyn Y, Burns KD, Testani JM, et al. Renal hemodynamics and renin-angiotensin-aldosterone system profiles in patients with heart failure. J Card Fail. 2022;28:385\u201393.","journal-title":"J Card Fail"},{"key":"3530_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2459\/JCM.0b013e328364129c","volume":"15","author":"A Mignano","year":"2014","unstructured":"Mignano A, Pitruzzella V, Arnone G, et al. Prognostic role of aldosterone in patients with acute coronary syndrome: short and medium term follow-up. J Cardiovasc Med (Hagerstown). 2014;15:27\u201332.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"3530_CR65","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/jhh.2013.13","volume":"27","author":"V Tzamou","year":"2013","unstructured":"Tzamou V, Vyssoulis G, Karpanou E, Kyvelou SM, Gialernios T, Stefanadis C. Aldosterone levels and inflammatory stimulation in essential hypertensive patients. J Hum Hypertens. 2013;27:535\u20138.","journal-title":"J Hum Hypertens"},{"key":"3530_CR66","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1210\/clinem\/dgaa356","volume":"105","author":"C van der Heijden","year":"2020","unstructured":"van der Heijden C, Ter Horst R, van den Munckhof ICL, et al. Vasculometabolic and inflammatory effects of aldosterone in obesity. J Clin Endocrinol Metab. 2020;105:2719\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR67","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/jch.14593","volume":"24","author":"B Yazdani","year":"2022","unstructured":"Yazdani B, Delgado GE, Kleber ME, et al. The renin-angiotensin-aldosterone system, neurohumoral axis and cardiovascular mortality in LURIC. J Clin Hypertens (Greenwich). 2022;24:1587\u201397.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3530_CR68","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/cvr\/cvac019","volume":"119","author":"N Arnold","year":"2023","unstructured":"Arnold N, Hermanns IM, Schulz A, et al. Renin, aldosterone, the aldosterone-to-renin ratio, and incident hypertension among normotensive subjects from the general population. Cardiovasc Res. 2023;119:294\u2013301.","journal-title":"Cardiovasc Res"},{"key":"3530_CR69","doi-asserted-by":"publisher","first-page":"e002505","DOI":"10.1161\/JAHA.115.002505","volume":"4","author":"A Buglioni","year":"2015","unstructured":"Buglioni A, Cannone V, Sangaralingham SJ, et al. Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: a 4-year follow-up. J Am Heart Assoc. 2015;4:e002505.","journal-title":"J Am Heart Assoc"},{"key":"3530_CR70","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.psyneuen.2013.03.015","volume":"38","author":"S H\u00e4fner","year":"2013","unstructured":"H\u00e4fner S, Baumert J, Emeny RT, et al. Hypertension and depressed symptomatology: a cluster related to the activation of the renin-angiotensin-aldosterone system (RAAS). Findings from population based KORA F4 study. Psychoneuroendocrinology. 2013;38:2065\u201374.","journal-title":"Psychoneuroendocrinology"},{"key":"3530_CR71","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.ijcard.2012.05.034","volume":"167","author":"MA Hillaert","year":"2013","unstructured":"Hillaert MA, Lentjes EG, Kemperman H, et al. Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. Int J Cardiol. 2013;167:1929\u201335.","journal-title":"Int J Cardiol"},{"key":"3530_CR72","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac167","volume":"7","author":"K Inoue","year":"2022","unstructured":"Inoue K, Horikoshi H, Omura M, Tsurutani Y, Saito J, Nishikawa T. Association between aldosterone and hypertension among patients with overt and subclinical hypercortisolism. J Endocr Soc. 2022;7:bvac167.","journal-title":"J Endocr Soc"},{"key":"3530_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/eurjhf\/hfs173","volume":"15","author":"BA Maron","year":"2013","unstructured":"Maron BA, Opotowsky AR, Landzberg MJ, Loscalzo J, Waxman AB, Leopold JA. Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study. Eur J Heart Fail. 2013;15:277\u201383.","journal-title":"Eur J Heart Fail"},{"key":"3530_CR74","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ajh\/hpu115","volume":"28","author":"M Satoh","year":"2015","unstructured":"Satoh M, Kikuya M, Hosaka M, et al. Association of aldosterone-to-renin ratio with hypertension differs by sodium intake: the Ohasama study. Am J Hypertens. 2015;28:208\u201315.","journal-title":"Am J Hypertens"},{"key":"3530_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5530\/jcdr.2016.4.1","volume":"7","author":"H Basavanagowdappa","year":"2016","unstructured":"Basavanagowdappa H, Basavanagowdappa N, Ravikumar YS, Praveen K, Devegowda D. Magnitude of resistant hypertension and impact of aldosterone to renin ratio in resistant hypertension. J Cardiovasc Dis Res. 2016;7:133\u20138.","journal-title":"J Cardiovasc Dis Res"},{"key":"3530_CR76","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2459\/JCM.0000000000000190","volume":"16","author":"M Gregori","year":"2015","unstructured":"Gregori M, Giammarioli B, Tocci G, et al. Synergic effects of renin and aldosterone on right ventricular function in hypertension: a tissue Doppler study. J Cardiovasc Med (Hagerstown). 2015;16:831\u20138.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"3530_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031007","author":"K Mi\u0119tkiewska-Szwacka","year":"2023","unstructured":"Mi\u0119tkiewska-Szwacka K, Krauze T, Barecka K, et al. Comparison of hemodynamic response between patients with systolic heart failure differing in serum aldosterone concentrations during and after a 6-minute walk test. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12031007.","journal-title":"J Clin Med"},{"key":"3530_CR78","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1002\/ejhf.2986","volume":"25","author":"L Monzo","year":"2023","unstructured":"Monzo L, Huttin O, Ferreira JP, et al. Role of aldosterone in mid- and long-term left ventricular remodelling after acute myocardial infarction: the REMI study. Eur J Heart Fail. 2023;25:1742\u201352.","journal-title":"Eur J Heart Fail"},{"key":"3530_CR79","first-page":"36","volume":"10","author":"V Nesarhosseini","year":"2019","unstructured":"Nesarhosseini V, Mohsenipouya H, Makhlough A, Jalalian R. The relationship between aldosterone level and various LV conditions in patients with end-stage renal disease. Caspian J Intern Med. 2019;10:36\u201341.","journal-title":"Caspian J Intern Med"},{"key":"3530_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8071045","author":"SM Park","year":"2019","unstructured":"Park SM, Kim MN, Kim S, Shim WJ. Serum aldosterone is related to left ventricular geometry and function in young adults with never-treated primary hypertension. J Clin Med. 2019. https:\/\/doi.org\/10.3390\/jcm8071045.","journal-title":"J Clin Med"},{"key":"3530_CR81","first-page":"406","volume":"53","author":"N Resi\u0107","year":"2018","unstructured":"Resi\u0107 N, Dili\u0107 M, Durak-Nalbanti\u0107 A, et al. Serum aldosterone as a predictor of heart rhythm disorders in acute myocardial infarction. Folia Medica Facultatis Medicinae Universitatis Saraeviensis. 2018;53:406\u2013409.","journal-title":"Folia Medica Facultatis Medicinae Universitatis Saraeviensis"},{"key":"3530_CR82","doi-asserted-by":"publisher","first-page":"406","DOI":"10.5455\/medarh.2018.72.406-409","volume":"72","author":"N Resic","year":"2018","unstructured":"Resic N, Durak-Nalbantic A, Dzubur A, Begic A, Begic E. Serum aldosterone as predictor of progression of coronary heart disease in patients without signs of heart failure after acute myocardial infarction. Med Arch. 2018;72:406\u20139.","journal-title":"Med Arch"},{"key":"3530_CR83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5830\/CVJA-2019-059","volume":"31","author":"JM van Rooyen","year":"2020","unstructured":"van Rooyen JM, Poglitsch M, Huisman HW, Gafane-Matemane LF, Breet Y, Malan L. A primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in black men: the SABPA study. Cardiovasc J Afr. 2020;31:130\u20135.","journal-title":"Cardiovasc J Afr"},{"key":"3530_CR84","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/ajh\/hpad050","volume":"36","author":"V Varadarajan","year":"2023","unstructured":"Varadarajan V, Marques MD, Venkatesh BA, et al. Cardiovascular interactions of renin-angiotensin-aldosterone system assessed by cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2023;36:517\u201323.","journal-title":"Am J Hypertens"},{"key":"3530_CR85","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2013.278","volume":"85","author":"N Issa","year":"2014","unstructured":"Issa N, Ortiz F, Reule SA, et al. The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney Int. 2014;85:404\u201315.","journal-title":"Kidney Int"},{"key":"3530_CR86","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/HJH.0000000000003049","volume":"40","author":"M Lin","year":"2022","unstructured":"Lin M, Heizhati M, Gan L, et al. Higher aldosterone is associated with increased renal impairment risk in patients with hypertension and abnormal glucose metabolism: a longitudinal study. J Hypertens. 2022;40:561\u20139.","journal-title":"J Hypertens"},{"key":"3530_CR87","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1161\/HYPERTENSIONAHA.114.03231","volume":"63","author":"JM Brown","year":"2014","unstructured":"Brown JM, Underwood PC, Ferri C, et al. Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertension. 2014;63:1205\u201311.","journal-title":"Hypertension"},{"key":"3530_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100465","volume":"4","author":"JG Amatruda","year":"2022","unstructured":"Amatruda JG, Scherzer R, Rao VS, et al. Renin-angiotensin-aldosterone system activation and diuretic response in ambulatory patients with heart failure. Kidney Med. 2022;4:100465.","journal-title":"Kidney Med"},{"key":"3530_CR89","first-page":"561","volume":"18","author":"FKI AL-Mahdawi","year":"2018","unstructured":"AL-Mahdawi FKI, Sultan AS, AL-Wandi NKMA. Evaluation of renin-angiotensin-aldosterone system and cortisol levels in chronic renal failure. Biochem Cell Arch. 2018;18:561\u20136.","journal-title":"Biochem Cell Arch"},{"key":"3530_CR90","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.935615","volume":"28","author":"M Higa","year":"2022","unstructured":"Higa M, Ichijo T, Hirose T. Aldosterone-to-renin ratio is associated with diabetic nephropathy in type 2 diabetic patients: a single-center retrospective study. Med Sci Monit. 2022;28:e935615.","journal-title":"Med Sci Monit"},{"key":"3530_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002558","author":"C Then","year":"2022","unstructured":"Then C, Ritzel K, Herder C, et al. Association of renin and aldosterone with glucose metabolism in a Western European population: the KORA F4\/FF4 study. BMJ Open Diabetes Res Care. 2022. https:\/\/doi.org\/10.1136\/bmjdrc-2021-002558.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3530_CR92","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009890","volume":"7","author":"JJ Joseph","year":"2018","unstructured":"Joseph JJ, Echouffo Tcheugui JB, Effoe VS, Hsueh WA, Allison MA, Golden SH. Renin-angiotensin-aldosterone system, glucose metabolism and incident type 2 diabetes mellitus: MESA. J Am Heart Assoc. 2018;7:e009890.","journal-title":"J Am Heart Assoc"},{"key":"3530_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084362","volume":"9","author":"A Barcelo","year":"2014","unstructured":"Barcelo A, Pierola J, Esquinas C, et al. Relationship between aldosterone and the metabolic syndrome in patients with obstructive sleep apnea hypopnea syndrome: effect of continuous positive airway pressure treatment. PLoS ONE. 2014;9:e84362.","journal-title":"PLoS ONE"},{"key":"3530_CR94","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/ajh\/hpac091","volume":"35","author":"P Koo","year":"2022","unstructured":"Koo P, Muntner P, Hall ME, Gjelsvik A, McCool FD, Eaton CB. Relationship between risks for obstructive sleep apnea, resistant hypertension, and aldosterone among African American adults in the Jackson Heart Study. Am J Hypertens. 2022;35:875\u201383.","journal-title":"Am J Hypertens"},{"key":"3530_CR95","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5603\/AH.2015.0003","volume":"19","author":"M So\u0142tysiak","year":"2015","unstructured":"So\u0142tysiak M, Miazgowski T, Jaroszy\u0144ska E, Janowska A, Widecka K. Impaired aldosterone response to the saline infusion test in patients with resistant hypertension and obstructive sleep apnea. Arterial Hypertens. 2015;19:13\u20138.","journal-title":"Arterial Hypertens"},{"key":"3530_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1016804","volume":"13","author":"H Wang","year":"2022","unstructured":"Wang H, Heizhati M, Li N, et al. Association of objective and subjective parameters of obstructive sleep apnea with plasma aldosterone concentration in 2,066 hypertensive and 25,368 general population. Front Endocrinol (Lausanne). 2022;13:1016804.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3530_CR97","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.2337\/dc12-2562","volume":"36","author":"SK Musani","year":"2013","unstructured":"Musani SK, Vasan RS, Bidulescu A, et al. Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care. 2013;36:3084\u201392.","journal-title":"Diabetes Care"},{"key":"3530_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17070797","author":"N Munoz-Durango","year":"2016","unstructured":"Munoz-Durango N, Fuentes CA, Castillo AE, et al. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17070797.","journal-title":"Int J Mol Sci"},{"key":"3530_CR99","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jchf.2017.05.012","volume":"5","author":"JJ Joseph","year":"2017","unstructured":"Joseph JJ, Echouffo-Tcheugui JB, Kalyani RR, et al. Aldosterone, renin, cardiovascular events, and all-cause mortality among African Americans: the Jackson Heart Study. JACC Heart Fail. 2017;5:642\u201351.","journal-title":"JACC Heart Fail"},{"key":"3530_CR100","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3803\/EnM.2023.1789","volume":"38","author":"J Ha","year":"2023","unstructured":"Ha J, Park JH, Kim KJ, et al. 2023 Korean Endocrine Society consensus guidelines for the diagnosis and management of primary aldosteronism. Endocrinol Metab (Seoul). 2023;38:597\u2013618.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"3530_CR101","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ajh\/hpad032","volume":"36","author":"A Mansur","year":"2023","unstructured":"Mansur A, Vaidya A, Turchin A. Using renin activity to guide mineralocorticoid receptor antagonist therapy in patients with low renin and hypertension. Am J Hypertens. 2023;36:455\u201361.","journal-title":"Am J Hypertens"},{"key":"3530_CR102","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6:464\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3530_CR103","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/jhh.2014.33","volume":"29","author":"SR Collier","year":"2015","unstructured":"Collier SR, Sandberg K, Moody AM, et al. Reduction of plasma aldosterone and arterial stiffness in obese pre- and stage1 hypertensive subjects after aerobic exercise. J Hum Hypertens. 2015;29:53\u20137.","journal-title":"J Hum Hypertens"},{"key":"3530_CR104","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3530_CR105","first-page":"CD004022","volume":"4","author":"NA Graudal","year":"2017","unstructured":"Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev. 2017;4:CD004022.","journal-title":"Cochrane Database Syst Rev"},{"key":"3530_CR106","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-015-0372-3","volume":"75","author":"D Glicklich","year":"2015","unstructured":"Glicklich D, Frishman WH. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. Drugs. 2015;75:473\u201385.","journal-title":"Drugs"},{"key":"3530_CR107","first-page":"139","volume":"6","author":"N Kumar","year":"2013","unstructured":"Kumar N, Calhoun DA, Dudenbostel T. Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control. 2013;6:139\u201351.","journal-title":"Integr Blood Press Control"},{"key":"3530_CR108","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.842875","volume":"9","author":"W Zeng","year":"2022","unstructured":"Zeng W, Chu TTW, Ho CS, et al. Lack of effects of renin-angiotensin-aldosterone system activity and beta-adrenoceptor pathway polymorphisms on the response to bisoprolol in hypertension. Front Cardiovasc Med. 2022;9:842875.","journal-title":"Front Cardiovasc Med"},{"key":"3530_CR109","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1161\/HYPERTENSIONAHA.123.20894","volume":"80","author":"JE Ebinger","year":"2023","unstructured":"Ebinger JE, Gluckman TJ, Magraner J, et al. Characterization of individuals with apparent resistant hypertension using contemporary guidelines: Insights from CV-QUIC. Hypertension. 2023;80:1845\u201355.","journal-title":"Hypertension"},{"key":"3530_CR110","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.amjcard.2019.09.033","volume":"125","author":"AM Maw","year":"2020","unstructured":"Maw AM, Thompson LE, Ho PM, et al. Implications of guideline updates for the management of apparent treatment resistant hypertension in the United States (A NCDR Research to Practice [R2P] Project). Am J Cardiol. 2020;125:63\u20137.","journal-title":"Am J Cardiol"},{"key":"3530_CR111","unstructured":"Mangat G, Sharma. ISPOR. 2023. https:\/\/www.ispor.org\/docs\/default-source\/intl2023\/ispor23gsinghmsr36poster-pdf.pdf?sfvrsn=a41c2783_0. Accessed Nov 2024."},{"key":"3530_CR112","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/M20-4873","volume":"174","author":"JB Cohen","year":"2021","unstructured":"Cohen JB, Cohen DL, Herman DS, Leppert JT, Byrd JB, Bhalla V. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: a retrospective cohort study. Ann Intern Med. 2021;174:289\u201397.","journal-title":"Ann Intern Med"},{"key":"3530_CR113","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1161\/HYPERTENSIONAHA.121.18118","volume":"79","author":"GL Hundemer","year":"2022","unstructured":"Hundemer GL, Imsirovic H, Vaidya A, et al. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: a population-based retrospective cohort study. Hypertension. 2022;79:178\u201386.","journal-title":"Hypertension"},{"key":"3530_CR114","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","volume":"75","author":"G Jaffe","year":"2020","unstructured":"Jaffe G, Gray Z, Krishnan G, et al. Screening rates for primary aldosteronism in resistant hypertension: a cohort study. Hypertension. 2020;75:650\u20139.","journal-title":"Hypertension"},{"key":"3530_CR115","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12913-022-07788-8","volume":"22","author":"O Suntornlohanakul","year":"2022","unstructured":"Suntornlohanakul O, Sakarin S, Kietsiriroje N, Sriplung H. Geographical inequality in service utilization for primary aldosteronism screening: spatial epidemiological study in Southern Thailand. BMC Health Serv Res. 2022;22:458.","journal-title":"BMC Health Serv Res"},{"key":"3530_CR116","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"3530_CR117","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR, et al. Primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2025;110:2453\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR118","doi-asserted-by":"publisher","unstructured":"Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;86(18). https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007.","DOI":"10.1016\/j.jacc.2025.05.007"},{"key":"3530_CR119","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/s41440-023-01325-8","volume":"46","author":"R Morita","year":"2023","unstructured":"Morita R, Azushima K, Sunohara S, et al. High plasma aldosterone concentration is associated with worse 24-h ambulatory blood pressure profile in patients with primary aldosteronism. Hypertens Res. 2023;46:1995\u20132004.","journal-title":"Hypertens Res"},{"key":"3530_CR120","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034180","volume":"13","author":"K Inoue","year":"2024","unstructured":"Inoue K, Naito T, Fuji R, et al. Primary aldosteronism and risk of cardiovascular outcomes: genome-wide association and Mendelian randomization study. J Am Heart Assoc. 2024;13:e034180.","journal-title":"J Am Heart Assoc"},{"key":"3530_CR121","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1210\/clinem\/dgae145","volume":"109","author":"WW Parksook","year":"2024","unstructured":"Parksook WW, Brown JM, Omata K, et al. The spectrum of dysregulated aldosterone production: an international human physiology study. J Clin Endocrinol Metab. 2024;109:2220\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR122","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/clinem\/dgaa606","volume":"105","author":"A Vaidya","year":"2020","unstructured":"Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach. J Clin Endocrinol Metab. 2020;105:3771\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"3530_CR123","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"3530_CR124","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"3530_CR125","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474\u201384.","journal-title":"Eur Heart J"},{"key":"3530_CR126","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","volume":"151","author":"J Hu","year":"2025","unstructured":"Hu J, Zhou Q, Sun Y, et al. Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial. Circulation. 2025;151:196\u20138.","journal-title":"Circulation"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03530-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03530-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:28:23Z","timestamp":1778581703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03530-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":126,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3530"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03530-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abiy Agiro, Shan Luan, and Joanna Huang are employees and stockholders of AstraZeneca. Gianfranco Parati has received honoraria for lectures from Omron, SOMNOmedics AG, Merck, and Viatris. Gbenga Ogedegbe is funded by the American Heart Association and the National Institutes of Health (NHLBI, NIMHD, AHRQ, and PCORI). He also received honorarium from AstraZeneca as a Visiting Professor to discuss strategies to address health inequities in hypertension. Harrison Davis, Ian Daniel, and Jan McKendrick were employees of Avalere Health, which is a consulting firm that received payment from AstraZeneca to conduct the study, at the time the study was undertaken. Raymond R. Townsend received consulting fees from Medtronic, Regeneron, Bard, Orchestra Backbeat, Idorsia and AstraZeneca; serves on DSMBs for Cytel, Novartis and E*Star; and received royalty income from UpToDate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}